COVID-19 has spread globally, and large number of clinical trials are ongoing to develop COVID-19 therapy. Anti-malarial drug hydroxychloroquine (HCQ) is one of the drugs against COVID-19 in clinical trials. However, several recent clinical studies have reported the HCQ-induced cardiotoxicities, such as Torsade de Pointes (TdP). Since drug-induced cardiotoxicity is one of the key issues before clinical trials, non-clinical assessment would be also important for COVID-19 treatments. In the present study, we assessed HCQ-induced cardiotoxicity, such as proarrhythmia and contraction with iPSC-cardiomyocytes (hiPSC-CMs). We used iCell cardiomyocyte 2.0 (CDI) as hiPSC-CMs. Proarrhythmia risk was evaluated by multi-electrode array system (MED64, Alpha Med Scientific). Contraction analyses were carried out using motion vector prediction method (SI8000, Sony). Treatment with HCQ induced early afterdepolarization, which is known to trigger TdP, and caused arrest at a higher concentration in hiPSC-CMs. HCQ decreased the amplitude of 1^st peak of field potentials in a dose-dependent manner, suggesting that HCQ inhibited I_Na currents. We next assessed the proarrhythmia risk of HCQ using 2D TdP risk categorization map. As a result, HCQ was categorized into a high-risk group. In addition, HCQ decreased contractility in a dose-dependent manner. Taken together, these data suggest that HCQ induced proarrhythmia risk and contraction impairment in iPSC-CMs. Therefore, hiPSC-CMs would be a useful tool to assess comprehensive cardiotoxicity at non-clinical settings.